Michael Cheng

Dr. Michael L. Cheng is a physician scientist at the University of California San Francisco (UCSF) specializing in medical oncology, with a focus on non-small cell lung cancer (NSCLC) and precision oncology. He integrates cancer genomics into clinical practice to tailor treatments using targeted therapies and immunotherapies.

• Education:
  • BA in Molecular and Cell Biology, University of California, Berkeley
  • MD, University of California, Los Angeles
  • Residency in Internal Medicine, UCSF
  • Fellowship in Medical Oncology, Memorial Sloan Kettering Cancer Center

Research Interests center on advancing cancer genomics, developing targeted therapies, and optimizing immunotherapies through clinical trials. His work explores mechanisms of drug resistance, biomarker discovery (e.g., BRCA2 reversion mutations, ATM mutations), and liquid biopsy applications via plasma cfDNA genotyping.

Scientific Awards include the

• Conquer Cancer Foundation of ASCO Career Development Award
• Alpha Omega Alpha Honor Society
• PCF Young Investigator Award
• Phi Beta Kappa Honor Society

Key Publications highlight advancements in precision therapies for NSCLC, BET inhibitors for NUT carcinoma, and genomic profiling of treatment resistance mechanisms.